[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628076":3},{"organization":4,"outcomesModule":7,"designInfo":15,"detailedDescription":11,"studyPopulation":18,"armGroups":11,"interventions":11,"overallOfficials":11,"centralContacts":19,"locations":28,"responsibleParty":58,"collaborators":11,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":11,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":11,"enrollmentInfo":69,"targetDuration":11,"studyType":72,"phases":11,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":77,"whyStopped":11,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Tools4Patient","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Proportion of attended MOUD medication visits",null,"Observation period will be three (3) months.",{"measure":14,"description":11,"timeFrame":12},"Proportion of prescribed doses taken",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":16,"timePerspective":17,"maskingInfo":11},"CASE_ONLY","PROSPECTIVE","Adult participants initiating or receiving MOUD in community-based and specialty clinics",[20,25],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"Chantal Gossuin","CONTACT","+32(0)71140200","chantal.gossuin@cognivia.com",{"name":26,"role":22,"phone":23,"phoneExt":11,"email":27},"Laura Onckelinx","laura.onckelinx@cognivia.com",[29,47],{"facility":30,"status":11,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"SOAP MAT, LLC - Central","San Diego","California","92115","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-117.16472,32.71571,{"lat":40,"lon":39},[43],{"name":44,"role":22,"phone":45,"phoneExt":11,"email":46},"Laura Rossi","(760) 305-7528","drlaura@soapmat.com",{"facility":48,"status":11,"city":49,"state":32,"zip":50,"country":34,"countryCode":35,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"SOAP MAT, LLC - Vista","Vista","92083",{"type":37,"coordinates":52},[53,54],-117.24254,33.20004,{"lat":54,"lon":53},[57],{"name":44,"role":22,"phone":45,"phoneExt":11,"email":46},{"type":59,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100628076","real-world-evaluation-of-compl-ai-for-predicting-early-medication-dropout-in-opioid-use-disorder-treatment-100628076",false,"NCT07456930","Real-World Evaluation of Compl-AI for Predicting Early Medication Dropout in Opioid Use Disorder Treatment","Real-World Assessment of Compl-AI in Predicting Early Discontinuation of Medication for Treatment of Opioid Use Disorder (MOUD) in Community and Specialty Treatment Programs","Inclusion Criteria:\n\n* Ability to understand and provide written informed consent.\n* Male and female participant 18 years of age at the time of consent.\n* Participant with OUD based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).\n* Eligible to receive MOUD per site standard of care or currently receiving MOUD initiated prior to study enrollment.\n\nExclusion Criteria:\n\n* Cognitive impairment that precludes the ability to provide written informed consent.\n* Already enrolled in another study\u002Fprogram.","ALL","18 Years",{"count":70,"type":71},295,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn whether the Compl-AI model can accurately predict who is likely to stop their medication for opioid use disorder (MOUD) early in adults receiving real-world treatment for opioid use disorder (OUD).\n\nThe main questions it aims to answer is:\n\ncan the model accurately predict early discontinuation of MOUD?\n\nBecause this study has no comparison groups, all participants receive their usual MOUD as part of routine care. Researchers will observe how participants engage with treatment and how well Compl-AI predicts their outcomes.\n\nParticipants will complete 4 visits, including a questionnaire about personal experiences during first visit and questions about their substance use and treatment history.\n\nDuring the monthly study visits, the researchers will record in particular the attendance at MOUD medication visits, the medication adherence and any treatment discontinuation.",[75],"Opioid Use Disorder",[75],"NOT_YET_RECRUITING","2026-09-30",{"date":80,"type":81},"2026-10-01","ACTUAL",{"date":83,"type":71},"2027-06-01",{"date":85,"type":71},"2027-12",{"name":5,"class":6},2]